

## Index

## A

- abdomen, PET interpretation  
pitfalls 53–56
- abscess, soft tissue 250
- acetate, <sup>11</sup>C- 21
- adenocarcinoma  
ampulla of Vater 130  
esophagus 120, 121, 125  
gastric 126  
lung 97–98, 104, 110
- adenoma, colonic 53, 54
- adrenal tumors 155–156, 244  
secondary (from lung)  
106–108, 108
- Alzheimer disease 271,  
272–273, 274, 274–276
- American Academy of Otolaryngology—Head and Neck Surgery, classification of lymph node regions 77
- American Joint Commission (AJCC) staging  
bone tumors 196  
melanoma 188  
renal cell carcinoma 158  
testicular germ cell tumors 162
- American Joint Commission (AJCC)/UICC, T staging of head and neck cancer 79
- amino acids as radiotracers 21, 23
- brain tumors 68–69  
children 229  
differentiation from non-neoplastic lesions 70–71  
grading and prognosis 71–72  
lymphomas 73  
secondary (metastases) 73  
treatment response evaluation 72–73
- ammonia, <sup>13</sup>N- 22–23  
myocardial blood flow 23, 263
- ampulla of Vater, adenocarcinoma 130
- amyloid detection 274
- anaplastic astrocytoma 65
- anaplastic thyroid carcinoma 85, 86, 95
- anesthesia, pediatric 39, 40, 43
- angiography of coronary vessels, CT 266–267
- annihilation 6, 7, 8, 287
- antihormonal therapy, prostatic carcinoma 175
- apoptosis markers 240–241
- approximation methods 5–6
- arm position 34
- arthritis  
PET interpretation pitfalls 56  
rheumatoid 254, 259
- artifacts 47–49  
attenuation-correction 42, 46  
brown fat 38, 48, 49, 53  
skeletal 57
- astrocytomas 64–65, 73  
pediatric 74
- atherosclerosis (and atherosclerotic plaque) 264–265  
coronary 262, 266, 269
- attenuation 8, 9, 44–45  
coefficients 5, 287  
correction 11–12, 46–47  
artifacts 42, 46  
lymphomas and 186  
PET and low-dose CT for  
see low-dose CT
- autonomic cardiac innervation 263, 265
- axillary staging, breast cancer 142, 143
- B**
- back-projection 287  
CT 4  
PET 9
- benign tumors and lesions  
artifacts associated with 48  
differentiation from malignant  
brain 67  
female pelvis 145–146  
lymphoma 181  
melanoma 188–189  
musculoskeletal 194
- beta-plus (positron-emitting) particles 15  
decay 6–7
- biopsy  
brain tumors, planning 72  
thyroid cancer 87
- bladder 55  
diverticula 54, 55
- blood vessel see vascular system
- bone  
[<sup>18</sup>F]fluoride uptake 21  
fractures, PET interpretation pitfalls 56  
infection see osteomyelitis  
metastases see skeleton  
primary tumors 195–201, 245  
children 209, 215–222  
prognosis 205  
recurrence detection 206  
response to therapy 205–206
- bone island 197
- bone marrow  
infection see osteomyelitis  
lymphoma involvement 179  
PET interpretation pitfalls 56
- bone scans, children 216, 217, 219
- bowel see intestine
- brain  
anatomy 61  
degenerative disease 272–280  
high-resolution PET 283  
brain tumors 61–75, 242  
pediatric see children  
radiopharmaceuticals 66–74, 239  
secondary (metastases) 49, 66, 73  
from kidney 160  
from lung 108  
from unknown primary 232
- breast cancer/carcinoma 140–145  
as unknown primary 234
- bronchial carcinoma 31, 47, 98, 99, 100, 106
- bronchio(lo)alveolar carcinoma 98, 100, 111
- brown fat (and artifacts) 48  
abdomen 56  
chest 53  
FDG uptake in children 38  
head and neck 49  
lymphomas and 180
- C**
- calcifications  
coronary artery 266  
thyroid cancer 87
- camera design (PET) 9–10
- cancer see tumors
- carbon-11 PET radiotracers 20, 21–22, 23
- carcinoma (major mentions only)  
breast see breast cancer  
cervical 148–150  
cholangiocellular 135  
colorectal 53, 54, 138–139, 243  
esophageal 120–126  
hepatocellular 135  
lung 31, 32, 47, 97–113  
nasopharyngeal 78, 79, 80, 81  
pancreatic 128, 129  
prostatic see prostatic carcinoma  
renal cell 157–160  
small bowel 137  
thyroid 85–94, 242  
see also adenocarcinoma  
carcinoma in situ, ductal 140  
carcinomatosis, peritoneal see peritoneal carcinomatosis  
cardiovascular disease 261–270  
see also heart  
carotid artery stenosis 264  
cartilaginous tumors 194, 198–201
- catheter, venous 52
- cerebral tumors see brain tumors
- cervical fascia see fascia
- cervical lymph nodes 76, 77  
metastases of unknown origin 81, 234
- cervical soft tissues 75  
CT (in thyroid cancer) 88
- cervix, cancer 148–150
- chemotherapy  
bone marrow activation 56  
response evaluation  
esophageal carcinoma 125  
lung cancer 113  
lymphoma 179, 179–180  
testicular tumors 164–165
- chest, PET interpretation pitfalls 51–53
- children 37–44, 60, 209–231  
advantages of PET-CT 42–43  
brain tumors 74, 229–230  
amino acid uptake 71  
benign–malignant differentiation 67  
protocols 37  
CT 35, 37  
special requirements and problems 37–42  
tumors (other than brain) 209–229, 245
- cholangiocellular carcinoma 135
- choline, radiolabeled 22  
prostatic carcinoma 172, 172–173, 174, 174–175, 176
- chondrosarcoma 199–201
- coincidence (in CT) 8–9  
measurement 7–8
- colitis, ulcerative 256, 257

- colon, PET interpretation pitfalls 53, 54
- color scale 46
- colorectal carcinoma 53, 54, 138–139, 243
- computed tomography (CT) 3–5, 44–45
- adrenal tumors 156
- basic principles 3–5
- bladder cancer 161
- brain tumors 63–66, 67
- children 229
- breast cancer 142
- contrast *see* contrast-enhanced CT; contrast media
- endometrial cancer 151
- esophageal carcinoma 121
- fever of unknown origin 248
- gastric carcinoma 126–127, 127
- head and neck tumors 79–80, 81
- heart 261, 265–267
- coronary disease 261
- hepatoblastoma 228
- images 44–45
- data *see* data
- interpretation/analysis 44–45, 60
- rendering and reconstruction 3–5, 6, 9, 44–45
- inflammatory bowel disease 257
- low-dose *see* low-dose CT
- lung cancer
- non-small cell 99–100, 100–101, 103–104, 106–108, 109
- secondary 116
- lymphoma 181
- melanoma 191
- musculoskeletal tumors 205, 205–206, 206, 243
- bone tumors 195, 196, 216
- children 216
- soft-tissue tumors 201, 201–203
- neurodegenerative disease 272–273
- noncontrast 25
- ovarian cancer 146–147
- pancreatic tumors
- carcinoma 128
- islet cell tumor 131
- pleural mesothelioma 114
- prostatic carcinoma 171
- protocols 34–35
- children 35, 37
- spiral *see* spiral CT
- testicular germ cell tumors 163
- thyroid cancer 87–88
- consent (informed) 33
- children 38
- contrast-enhanced CT 25
- PET-CT with 30, 32
- selective 30, 32
- contrast media 25–30, 59
- brain tumors 63–64
- children 39–40
- head and neck tumors 80
- high concentration, artifacts due to 48
- positive and negative 25–26
- risk/adverse effects 27–28, 28–29
- co-registration, automatic/software-based 3, 30
- coronary arteries (and disease) 261, 262, 263, 264, 266–267, 269
- cost-benefit analysis, melanoma 193
- cost reduction in non-small cell lung cancer 111
- Crohn disease 256, 257, 259
- cyclotron 16–17, 287
- cystic pancreatic tumors 128
- D**
- data
- acquisition (in CT) 3–4, 34
- spiral CT 5, 289
- see also* volume acquisition
- raw (in CT)
- composition 8
- correction 8–9
- dementias 271–272, 272–273, 274–276
- density (CT)
- brain tumor 64
- determination 44–45
- 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose *see* fluorodeoxyglucose
- 3'-deoxy-3'-[<sup>18</sup>F]fluoro-L-thymidine *see* fluorothymidine
- detectors, PET 7
- diaphragmatic motion artifacts 53
- differentiated thyroid carcinoma (DTC) 85, 86
- multimodal treatment and diagnosis 88–93
- diffuse astrocytoma, pediatric 74
- digestive tract *see* gastrointestinal tract
- diverticula, bladder 54, 55
- documentation of PET 47
- L-DOPA, <sup>18</sup>F-labeled analog of 20
- medullary thyroid carcinoma 94
- neurodegenerative disease 273, 277
- pheochromocytoma 156
- dopamine-D<sub>2</sub>-receptor antagonist, <sup>11</sup>C-labeled 22
- neurodegenerative disease 273–274
- dose (radiation) 288
- and safety considerations 12
- children 40–42
- DOTATOC *see* gallium-67
- DOTATOC
- ductal carcinoma in situ (breast) 140
- duodenum 53
- somatostatinoma 131
- E**
- early detection/diagnosis
- Alzheimer disease 276
- breast cancer 140
- lung cancer (non-small cell) 100–101
- echocardiography 261
- edema (perifocal), brain tumor 64
- education and training 281–282
- effective dose 12, 13
- enchondroma 198
- endocarditis 253, 259
- endocrine gastrointestinal tumors 20, 131–132
- endometrial cancer 150–153
- endoscopy, cervical cancer 148
- see also* mediastinoscopy
- energy dose 12
- enhancement characteristics (CT), brain tumor 64
- Enneking system, bone tumors 196
- enostosis 197
- enteral contrast media 26, 33, 59
- enteroclysis, inflammatory bowel disease 257
- ependymoma 65–66
- epiphysis 57
- esophagus 52
- carcinoma 120–126
- ethmoid sinus tumors, T staging 79
- European Pharmacopoeia, FDG quality control 19
- Ewing sarcoma/tumor 197, 205, 206
- children 216, 217, 220, 221, 222, 223, 245
- examination 30–36
- protocols 30–36, 59–60
- children 27, 35
- technique 34–35
- brain tumor CT 63
- selection 34–35
- exostosis, osteocartilaginous 199
- expiration, mild 35
- extragonadal germ cell syndrome 234, 235
- extravasation of contrast media 27
- eye muscles, PET interpretation pitfalls 49
- F**
- false-negative findings
- head and neck cancer lymph node involvement on CT 80
- lung cancer, FDG PET 100, 111
- false-positive findings 44
- head and neck cancer lymph node involvement on CT 80
- lung cancer, FDG PET 111
- fascia, cervical 75–76
- spaced defined by 76–77
- fasting 33
- children 37
- FDG *see* fluorodeoxyglucose, <sup>18</sup>F- (FDG)
- females (women)
- bladder 160
- breast cancer *see* breast cancer
- genitalia *see* genitalia
- fever of unknown origin 248–249, 259
- fibrillary astrocytoma 64–65
- fibrohistiocytic tumors 201
- field of view (FOV) 10, 45
- FIGO staging
- cervical cancer 148, 149
- endometrial cancer 151
- ovarian cancer 146, 147
- filtered back-projection
- CT 4
- PET 9
- fluoride-18
- in FDG production 17–18
- production 16
- radiopharmaceuticals (other than FDG) containing 20–21, 23
- see also* sodium fluoride
- fluorine-18 (<sup>18</sup>F) 6, 7
- fluorodeoxyglucose, <sup>18</sup>F- (FDG) (general aspects only) 15, 17–18, 59
- uptake (general aspects)
- in brown fat in children 38
- focal 51
- mechanisms 17
- weight-adjusted activity in children 39
- see also specific conditions/lesions*

- fluorodihydrotestosterone (FDHT), <sup>18</sup>F-, prostatic carcinoma 172
- 6-fluoro-L-DOPA, <sup>18</sup>F- 20
- brain tumors 69
- O-(2-fluoroethyl)-L-tyrosine (FET), <sup>18</sup>F- 23
- brain tumors 68
- differentiation from non-neoplastic lesions 70
- grading and prognosis 70
- treatment response evaluation 72
- fluoromisonidazole, <sup>18</sup>F- ([<sup>18</sup>F] FMISO) 23
- fluorothymidine, <sup>18</sup>F- (and 3'-deoxy-3'-[<sup>18</sup>F]fluoro-L-thymidine/FLT) 23, 240
- brain tumors 69
- grading and prognosis 71
- follicular B cell lymphoma 31
- follicular thyroid carcinoma 86
- follow-up examinations
- brain tumors 73
- breast cancer 142
- cervical cancer 148
- lymphoma in children 214
- melanoma 192–193
- prostatic carcinoma 174–175
- see also* recurrence
- FP-TOCA, <sup>18</sup>F-, islet cell tumor 132
- fractures, PET interpretation pitfalls 56
- frontotemporal dementia 272, 273, 276, 278
- fusion images 1
- children
- errors 42
- optimal 42–43
- G**
- gallium-67 DOTATOC
- islet cell tumors 132
- medullary thyroid carcinoma 94
- small bowel carcinoma 137
- gamma radiation 6–7
- personnel safety 13
- gantry aperture size 10–11
- Gardner syndrome 198
- gastric lesions *see* stomach
- gastrinoma 131
- gastroesophageal junction adenocarcinoma 121
- gastrointestinal (digestive) tract contrast media 26, 33, 59
- PET interpretation pitfalls 53
- tumors 53, 54, 120–134, 243
- endocrine 20, 131–132
- lower 137–139, 243
- stromal 131, 132, 137
- upper 120–134, 243
- general anesthesia, pediatric 39, 40, 43
- genitalia
- females
- PET interpretation pitfalls 55
- tumors 145–152, 243–244
- males
- PET interpretation pitfalls 55
- tumors 162–167, 244
- germ cell tumors, male 162, 243
- see also* extragonadal germ cell syndrome
- giant cell arteritis 254, 255
- giant cell tumor of bone 201
- glioblastoma 62–63, 65, 67, 68
- glioma 62–63, 64–65
- malignant progression 62
- gliomatosis cerebri 65
- glucose
- patient levels 33
- see also* fasting
- transporters 17
- grade/grading
- bone tumors 195–196
- brain tumor 71–72
- soft-tissue tumors 201
- graft, vascular, infection 252
- granulomatous inflammations 254
- gray scale 44
- gynecology *see* breast cancer; genitalia
- H**
- half-lives 7, 287
- head and neck 75–84
- anatomy 75–77
- PET interpretation pitfalls 49
- tumors 75–84, 242
- occult (cancer of unknown primary) 81, 234
- radiotherapy *see* radiotherapy
- heart
- CT *see* computed tomography
- endocarditis 253, 259
- failure 269
- global function 267
- see also* coronary arteries; myocardium
- helical CT *see* spiral CT
- hepatocellular carcinoma 135
- heterotopic ossification 205
- high-precision intensity-modulated radiotherapy 241
- high-resolution PET 283, 284
- histiocytic sarcoma 203, 204
- histiocytoma, malignant fibrous 200
- histiocytosis, Langerhans cell 227–228
- Hodgkin disease 177, 178, 179, 180, 181, 184, 185, 243
- pediatric 209–210, 212, 214, 215
- Hounsfield scale/units 5, 287
- Huntington disease 272, 273, 277, 279
- hydroxyephedrine, <sup>11</sup>C- ([<sup>11</sup>C] HED) 23
- pheochromocytoma 156
- 5-hydroxytryptophan (5-HTP), medullary thyroid carcinoma 94
- hypernephroma (renal cell carcinoma) 157–160
- hypopharynx
- anatomy 75
- synovial sarcoma 225
- T staging of tumors 79
- hypoxia markers 82, 240, 241
- I**
- images 44–58, 60
- CT *see* computed tomography
- fusion *see* fusion images
- PET *see* positron emission tomography
- PET-CT, interpretation 47
- implants and prostheses
- joint, infections 251–252
- metal 48, 53, 251
- incidental finding of colorectal carcinoma 139
- indium-111-leukocyte scans, inflammatory diseases 248
- indium-111-octreotide scintigraphy
- pancreatic islet cell tumors 131, 132
- small bowel malignancy 137
- infants, fasting 38
- infections 247, 248–253
- inflammations 247–256
- hypermetabolism 48–49
- in bone 57
- informed consent *see* consent
- injection site, breast cancer PET 144–145
- inspiration depth 35
- insulinoma 131
- interdisciplinary and multidisciplinary teamwork 1
- children 43
- see also* personnel
- intestine (bowel)
- contrast media 26, 33, 59
- inflammatory bowel disease 256–257, 259
- PET interpretation pitfalls 53
- tumors 53, 54, 137–139, 243
- MALT lymphoma 53
- intravascular contrast media
- see* parenteral contrast
- iodinated contrast media 25–26, 26, 27, 28
- iodine-123 scintigraphy
- neuroblastoma 224
- pheochromocytoma 156
- iodine-124 PET tracers 23
- iodine-124 scintigraphy in thyroid cancer, for recurrence detection 93
- iodine-131 scintigraphy in thyroid cancer
- postoperative staging 90
- in suspected recurrence 90, 93
- iodine-131 therapy in thyroid cancer 89
- non-option in medullary carcinoma 93
- islet cell tumors 131–132
- J**
- joints
- PET interpretation pitfalls 56
- prosthetic, infections 251–252
- see also* arthritis
- K**
- kernel 4, 287
- kidney
- cancer 157–160, 243
- children 228, 229
- contrast-induced adverse effects 27–28, 59
- PET interpretation pitfalls 55
- L**
- Langerhans cell histiocytosis 227–228
- large cell carcinoma of lung 102
- large intestine 53
- tumors 138–139, 243
- laryngeal tumors 78
- T staging 79
- legal requirements 13
- leukocyte scans, inflammatory diseases 248
- Lewy body dementia 272, 273, 276
- line of response 8, 287
- lip cancer, T staging 79
- liver 135–136
- metastases 135–136, 243
- from lung 106, 108
- from unknown primary 234–235

- PET interpretation pitfalls 55–56  
 primary cancer 135, 243  
   hepatoblastoma 228
- low-dose CT  
 image analysis 45  
 lymphoma 186  
 PET and, for attenuation correction 30, 32  
   children 41  
 PET-CT with 30, 30–32  
   whole-body 30, 32
- lung 51–52  
 nodules 35, 47, 51, 99, 100, 101  
 PET interpretation pitfalls 51–52
- lung cancer 97–113, 242  
 non-small cell *see* non-small cell lung  
 primary (carcinoma) 31, 32, 47  
 radiotherapy *see* radiotherapy  
 secondary (metastases) 116–117  
   from melanoma 190, 191  
   from rhabdomyosarcoma 33  
   from unknown primary 232, 234  
 small cell 112, 113–116, 242
- lymph nodes 47  
 image interpretation 47  
 lymphoma involvement 31, 181, 182  
 metastases *see* metastases, lymph node; N staging  
 neck *see* cervical lymph nodes  
 in staging *see* N staging; TNM
- lymphoma 177–187, 209–215, 243  
 bowel 53  
 cerebral 66, 73, 74  
 follicular B cell 31  
 gastric 127  
 MALT 53, 127  
 pediatric 209–215, 245  
 thyroid 95
- M**
- M staging (distant metastases in TNM system)  
 bone tumors 196, 197  
 breast cancer 141, 142  
 endometrial cancer 151  
 esophageal carcinoma 123–124  
 gastric carcinoma 126, 127  
 head and neck tumors 78
- lung cancer (non-small cell) 97, 103, 106–109  
 melanoma 188, 189–191  
 ovarian cancer 147  
 pancreatic cancer 128, 129  
 prostatic carcinoma 170, 171, 174  
 renal cell carcinoma 158, 159  
 testicular tumors 162, 163–164  
*see also* metastases, distant
- magnetic resonance imaging (MRI)  
 adrenal tumors 156  
 bladder cancer 161  
 brain tumors in children 229  
 cardiac 261  
   inflammatory cardiomyopathy 253  
 cervical cancer 148  
 head and neck tumors 80  
   vs PET 81  
 hepatoblastoma 228  
 inflammatory bowel disease 257  
 musculoskeletal tumors 205, 205–206, 206, 243  
 bone tumors 195, 196  
 soft-tissue tumors 201, 201–203
- magnetic resonance mammography 141–142
- males  
 bladder 160  
 genitalia *see* genitalia  
 prostatic carcinoma *see* prostatic carcinoma
- malignant tumors *see* tumors
- MALT lymphoma 53, 127
- mammography  
 conventional (X-ray) 140–141  
 in follow-up 142  
 MR 141–142
- mass, brain tumor 64
- maxillary sinus tumors, T staging 79
- mediastinum  
 endoscopy in lung cancer 104–106  
 PET interpretation pitfalls 52
- medullary thyroid carcinoma 85, 86, 93–94
- medulloblastoma 65  
 pediatric 65, 74
- melanoma 187–194, 243  
 metastases 57–58
- men *see* males
- meningioma 66
- mesenteric lymph node involvement, follicular lymphoma 31
- mesothelioma, pleural 114–116
- metabolic activity (in PET)  
 artifacts due to increases or decreases in 48–49  
 brain tumors 67  
 metaiodobenzylguanidine (MIBG) scintigraphy  
 neuroblastoma 224  
 pheochromocytoma 156
- metal implants 48, 53, 251
- metastases, distant  
 to adrenals 106–108, 108  
 from bone, children 216  
 cerebral *see* brain  
 from cervix 148  
 from head and neck cancer 81–82  
 from kidney 159, 160  
 from liver, screening 135  
 in liver *see* liver  
 from lung 106–108  
 in lung *see* lung  
 from melanoma 57–58  
 from ovaries 147  
 in pancreas 129, 130  
 skeletal *see* skeleton  
 in small bowel 137  
 from thyroid 87–88, 94  
 in thyroid 95  
 from unknown primary 232–235  
*see also* M staging
- metastases, lymph node  
 esophageal cancer, routes 120  
 PET interpretation pitfalls 50  
 thyroid cancer  
   CT 87  
   ultrasound 87  
 unknown primary 81, 232, 234  
*see also* N staging
- metformin and contrast media 28
- methionine, <sup>11</sup>C- (MET) 21  
 brain tumors in children 229  
 pancreatic cancer 129–131
- MIBG *see* metaiodobenzylguanidine
- monoclonal antibodies, inflammatory diseases 248
- motion artifacts 47  
 diaphragmatic 53  
 head and neck 49
- mucosa-associated lymphoid tissue (MALT) lymphoma 53, 127
- multidisciplinary teamwork *see* interdisciplinary and multidisciplinary teamwork
- multiphase CT 35
- multiple endocrine neoplasia (MEN) 131  
 medullary thyroid carcinoma in 86  
 pancreatic tumors 131
- multiple sclerosis 70, 71
- multislice spiral CT 6  
 heart 266
- multisystem atrophy 276–277
- muscle activity, PET interpretation pitfalls due to 48, 49, 57
- musculoskeletal system  
 infections 249–251, 259  
 tumors 194–208, 243  
   children 209, 215–222
- myocardium 261  
 assessment (viability/function etc.) 23, 261, 262–265  
 PET interpretation pitfalls 52
- myositis ossificans 205
- N**
- N staging (nodal involvement in TNM system)  
 bone tumors 196, 197  
 breast cancer 141, 142  
 endometrial cancer 151  
 esophageal carcinoma 123, 126  
 gastric carcinoma 126, 127  
 head and neck tumors  
   CT 78, 80  
   PET 81  
 lung cancer (non-small cell) 97, 98, 99, 103–104  
 melanoma 188, 189  
 ovarian cancer 147  
 pancreatic cancer 128, 129  
 prostatic carcinoma 170, 171, 174  
 renal cell carcinoma 158, 159  
 testicular tumors 162, 163–164  
 thyroid cancer 86  
*see also* metastases, lymph node
- nasal cavity tumors 78, 79
- nasopharynx  
 anatomy 75  
 carcinoma 78, 79, 80, 81
- neck *see* head and neck *and entries under* cervical
- neoadjuvant therapy 288  
 in esophageal carcinoma  
   chemotherapy 125  
   radiotherapy 125
- neoplasms *see* tumors
- nephroblastoma 228, 229
- nephropathy, contrast-induced 27–28, 59
- nerve supply, cardiac 265
- neuroblastoma 209, 221–227
- neurodegenerative disease 272–280
- neurons, presynaptic *see* presynaptic neurons
- nitrogen-13 PET radiotracers 20, 22–23

- nodules  
 pulmonary 35, 47, 51, 99, 100, 101  
 thyroid 86, 87
- noise equivalent count rate 10
- nonionic contrast media 26
- non-small cell lung cancer 97–109, 242  
 radiotherapy planning 238, 239
- O**
- octreotide, <sup>111</sup>In- *see* indium-111-octreotide scintigraphy
- octreotide analog *see* gallium-67 DOTATOC
- oligoastrocytoma 65
- oncology *see* tumors
- oral cavity  
 PET interpretation pitfalls 49  
 tumors  
 radiotherapy planning 237–238  
 T staging 79
- organ dose 12
- oropharynx  
 anatomy 75  
 T staging of tumors 79
- osseous/osteogenic tumors 194, 197–198
- ossification, heterotopic 205
- osteoblastoma 198
- osteocartilaginous exostosis 199
- osteochondroma 199
- osteoid osteoma 198
- osteoma 198
- osteomyelitis 57, 249–251, 259  
 prosthetic joint-associated 251–252
- osteosarcoma 197, 198, 199, 205  
 pediatric 215–216, 216, 218, 221, 245
- ovaries 145  
 cancer 146–148  
 PET interpretation pitfalls 55, 56
- oxygen-15 PET radiotracers 20, 23
- P**
- pancreatic tumors 128–132
- papillary thyroid carcinoma 86  
 recurrent 88, 91
- paranasal sinus tumors 78, 79
- parental role 39
- parenteral (incl. intravenous/intravascular) contrast media 26–28, 59  
 brain tumors 63–64
- Parkinson disease (and parkinsonism) 272, 273, 276–277, 278  
 with dementia 271
- parosteal osteosarcoma 198
- patient  
 aperture size 10–11  
 preparation 33–34, 59–60  
 positioning *see* positioning  
 radiation safety 12–13  
 selection for radiotherapy 236–239  
 table *see* table  
 time saving for 43
- pediatrics *see* children
- pelvis, female *see* genitalia
- performance parameters of PET systems 10
- perfusion imaging, myocardial 263–264
- peritoneal carcinomatosis 232  
 gastric cancer 127  
 ovarian cancer 147
- personnel/staff  
 pediatric examination, role 39  
 radiation safety 13–14  
*see also* interdisciplinary and multidisciplinary teamwork
- pharynx  
 anatomy 75  
 tumors 78, 79, 80, 81, 225  
 synovial sarcoma 225
- pheochromocytoma 155, 156, 157, 244
- photon absorption 44
- pilocytic astrocytoma 64  
 pediatric 74
- pitch (spiral CT) 5, 6, 288
- pleural mesothelioma 114–116
- pneumonia 51–52
- pneumonitis 52
- positioning, patient 3, 34  
 brain tumor CT 63  
 breast cancer PET 145  
 pediatric 42–43
- positron emission tomography/PET (major mentions only) 6–11, 46–58, 288  
 adrenal tumors 156  
 basic principles 6–11  
 bladder cancer 161  
 brain tumors 66–74  
 children 229  
 breast cancer 142–145  
 children 37  
 cholangiocellular carcinoma 135  
 colorectal cancer 138  
 esophageal carcinoma 123–124, 124–125, 126  
 FDG in *see* fluorodeoxyglucose
- fever of unknown origin 248–249
- gastric carcinoma 127
- head and neck tumors 80–84
- hepatoblastoma 228
- hepatocellular carcinoma 135
- high-resolution 283, 284
- image interpretation 46–47, 60
- pitfalls 47–58
- Langerhans cell histiocytosis 228
- liver cancer 135
- lung cancer  
 non-small cell 100, 101–103, 104–106, 108, 109  
 secondary 116–117  
 small cell 113
- lymphoma 179, 182–186  
 pediatric 210, 211, 214, 215  
 melanoma 189–190, 191  
 musculoskeletal tumors 205, 206  
 bone tumors 196, 197, 216, 217–219, 219, 221  
 children 216, 217–219, 219, 221  
 soft-tissue tumors 201, 203, 221
- myocardial assessment 261, 262–265
- neuroblastoma 224–227
- neurodegenerative disease 273–278
- pancreatic tumors  
 carcinoma 129–131  
 islet cell tumor 132
- pelvic tumors ♀ 145–146  
 endometrial cancer 151–152  
 ovarian cancer 146–147
- pleural mesothelioma 114
- prostatic carcinoma 171–175
- renal cell carcinoma 159–160
- testicular tumors 163–167
- thyroid carcinoma 90–93  
 medullary 93–94  
 unknown primary cancer 233–234, 234
- positron-emitting particles *see* beta-plus particles
- postoperative period in thyroid cancer  
 staging 90
- postsynaptic radiopharmaceutical markers 273–274
- presynaptic neurons  
 radiopharmaceutical markers 273
- striatal 20
- prognosis  
 Alzheimer disease 276
- brain tumors 71–72
- head and neck tumors 82–83
- lung cancer 111–113
- lymphoma 177, 180  
 children 214–215
- melanoma 187–188
- metastatic cancer with unknown primary 232
- musculoskeletal tumors 205
- thyroid cancer 93
- projections 288  
 CT 3, 4  
 algorithms 45  
 spiral CT 5  
 PET 9, 46  
*see also* back-projection
- proliferation markers 203, 241
- prostatic carcinoma 169–177, 243  
 pharmaceuticals 171–175, 239
- prostheses *see* implants and prostheses
- pulmonary tissues/lesions *see* lung
- pyrexia of unknown origin 248–249, 259
- Q**
- quality control, FDG 19
- quantification in PET 46  
 brain tumors 68, 69
- R**
- raclopride, <sup>11</sup>C- 22  
 neurodegenerative disease 273–274
- radiation safety *see* dose; safety considerations
- radiography *see* X-ray radiography
- radioiodine *see* iodine
- radiolabeling 15
- radionuclides (radioisotopes) 6, 7, 20, 288  
 production 16–17, 59  
 specific, in specific radiotracers 20, 20–21  
*see also* scintigraphy and specific radionuclides
- radiopharmaceuticals (radiotracers) 12, 14–23, 58–59  
 administration 33–34  
 children 38  
 brain tumors 66–74, 239  
 inflammatory diseases 247–248  
 neurodegenerative disease 273–274  
 new/innovative 69, 239–240  
 terminology 15–16, 59, 282

- uptake *see* uptake
- radiotherapy 236–242, 282
- brain tumors, planning 72
- esophageal carcinoma, neo-  
adjuvant 125
- future outlook 240–241
- head and neck tumors 78  
planning 84, 237–238
- lung cancer  
assessing response 113  
planning 238, 239
- lymphoma, planning 186
- PET interpretation following  
48
- planning (in general)  
236–242, 246
- random coincidence 8
- reconstruction index 6, 289
- rectal carcinoma 54, 138–139,  
243
- recurrence of tumors  
colorectal cancer, detection  
138–139
- detection and/or staging  
brain tumors 73  
breast cancer 144  
esophageal carcinoma  
124–125  
gastric carcinoma 127  
gynecologic tumors  
147–148, 244  
head and neck tumors 80  
liver metastases 136  
lung cancer 109–111  
lymphoma in children 214  
musculoskeletal tumors  
206, 219, 245  
pancreatic cancer 129  
prostatic carcinoma  
174–175  
renal cell carcinoma 160  
testicular germ cell tumors  
165–167  
thyroid cancer 87, 88,  
90–92
- prognosis, brain tumors 71  
*see also* follow-up
- region of interest (ROI) 34  
brain tumors 69  
contrast injection and 27  
semiautomatic definition 69
- renal cell carcinoma 157–160  
*see also* kidney
- research 282
- retinoblastoma 228–229
- rhabdomyosarcoma 224, 226  
pulmonary metastases 33
- rheumatoid arthritis 254, 259
- S**
- safety considerations (incl. ad-  
verse reactions)
- contrast media 27–28, 28–29  
radiation 12–14, 58  
children 40–42
- salivary glands  
PET interpretation pitfalls 49  
tumors 78, 79
- sarcoidosis 254
- sarcoma  
bone 197, 199–201  
children 215–222, 245  
in small bowel 137  
soft-tissue 201, 202, 203,  
204, 205  
children 221, 224, 225,  
226
- scattered coincidence 8, 8–9
- scintigraphy (radionuclide  
imaging) 289  
bone tumors in children  
216, 217, 219  
inflammatory diseases 248  
fever of unknown origin  
248  
melanoma 189  
neuroblastoma 224  
pancreatic islet cell tumors  
131, 132  
pheochromocytoma 156  
thyroid cancer  
postoperative 90  
recurrence detection and  
staging 90, 93
- screening  
for breast cancer 140, 142,  
143  
high-risk women 142  
for colorectal cancer 139  
for liver cancer metastasis (to  
other sites) 135  
for liver metastases (from  
other sites) 136
- sedation, pediatric 39, 43
- seminomas 163, 164, 165, 166
- sensitivity 289  
PET systems 10
- sentinel node scintigraphy,  
melanoma 189
- single-phase CT 35
- single photon emission com-  
puted tomography (SPECT)  
289  
myocardial 261
- sinogram 3–4, 289
- skeleton 56–58  
image interpretation of  
lesions 47  
pitfalls in PET 56–58  
metastases 56  
[<sup>18</sup>F] sodium fluoride with  
21  
image interpretation, and  
pitfalls 37, 56  
from kidney 160  
from lung 108
- from unknown primary  
232  
*see also* musculoskeletal  
system
- slice  
orientation, brain tumors 63  
thickness 5, 6, 45, 289
- small cell lung cancer 112,  
113–116, 242
- small intestine  
cancer 137, 243  
PET interpretation pitfalls 53
- sodium acetate *see* acetate
- sodium fluoride (NaF), <sup>18</sup>F- 21  
prostatic carcinoma 172, 174,  
243
- sodium iodide, <sup>124</sup>I- 23
- soft tissues  
abscess 250  
cervical *see* cervical soft  
tissues
- tumors derived from  
201–205, 245  
pediatric 209  
prognosis 205  
recurrence detection 206  
response to therapy  
205–206
- somatostatin receptor scintig-  
raphy *see* indium-111-  
octreotide scintigraphy
- sonography *see* ultrasound
- spatial resolution 10
- specific activity of radiophar-  
maceuticals 15–16
- spiral CT 5–6, 289  
heart 266  
pitch 5, 6, 288
- spleen, PET interpretation  
pitfalls 55
- squamous cell carcinoma  
esophagus 120, 121, 124  
head and neck  
distant metastases 78, 79  
lymph node metastases 82  
lung 32, 98, 102, 105, 107
- staff *see* personnel
- staging  
bone tumors 196–197, 198,  
245  
children 216  
breast cancer 140, 141, 142,  
142–144  
esophageal carcinoma  
120–124  
gastric cancer 126–127  
head and neck cancer  
CT 78  
PET 80–82  
lung cancer  
non-small cell 97, 100–109  
small cell 113  
lymphoma 179, 181  
pediatric 210–211
- melanoma 188, 189  
neuroblastoma 221, 224  
pancreatic cancer 128–129  
pelvic tumors (females)  
145–146, 243–244  
cervical cancer 148, 149  
endometrial cancer 151  
ovarian cancer 146, 147  
pleural mesothelioma 114  
prostatic carcinoma 170, 171,  
173–174  
radiotherapy planning and  
236  
renal cell carcinoma 158, 159  
soft-tissue tumors 201–203,  
205, 245  
testicular tumors 162,  
163–164  
thyroid cancer 86  
postoperative 90  
of recurrence 90–91  
TNM system *see* TNM staging  
system
- stomach  
carcinoma 126–127  
PET interpretation pitfalls 53
- striatal presynaptic neurons 20
- strip image 4, 289
- stromal tumor, gastrointestinal  
(GIST) 131, 132, 137
- surgery  
brain tumor 72  
testicular tumors 165  
thyroid cancer 88–89  
postoperative period *see*  
postoperative period
- sympathetic cardiac innerva-  
tion 263, 265
- synovial sarcoma 225
- T**
- T staging (primary size/extent  
in TNM system)  
bone tumors 196, 197  
breast cancer 141, 142–144  
endometrial cancer 151  
esophageal carcinoma 123  
gastric carcinoma 127, 128  
head and neck tumors  
CT 78  
PET 80–82  
lung cancer (non-small cell)  
97, 98, 100–103  
melanoma 188, 189  
ovarian cancer 147  
pancreatic cancer 129  
prostatic carcinoma 170, 171,  
173–174  
renal cell carcinoma 158–159  
testicular tumors 162, 163  
thyroid cancer 86

- table (patient) 11  
speed 6
- target volume, radiotherapy 236–239
- teaching/training/education 281–282
- technetium-99m scans  
inflammatory diseases 248  
thyroid cancer 248
- technical principles 3–13, 58
- technological advances 282–283
- temporal (giant cell) arteritis 254, 255
- tendon attachments 57
- teratoma, testicular 163, 164, 165
- testes  
germ cell tumors 162–167, 244  
PET interpretation pitfalls 55
- therapy *see* treatment
- thorax (chest), PET interpretation pitfalls 51–53
- 3D volume rendering technique and 3D reconstructions 45  
heart 266
- thymus 52–53
- thyroglobulin levels in thyroid cancer, postoperative 90
- thyroid cancer 85–94, 242
- thyroid function, contrast media effects 28
- thyroidectomy 88–89
- L-thyroxine replacement therapy 89
- time-of-flight technology 282, 283, 284
- time saving for patients and doctors 43
- TNM staging system  
bone tumors 196  
breast cancer 140, 141  
endometrial cancer 151  
esophageal carcinoma 123–124  
gastric carcinoma 126  
head and neck cancer 78  
lung cancer (non-small cell) 97, 98  
melanoma 188  
ovarian cancer 147  
pancreatic cancer 128–129  
prostatic carcinoma 170, 173–174  
renal cell carcinoma 158  
testicular tumors 162, 163  
thyroid cancer 86  
*see also* T; N; M
- tracers *see* radiopharmaceuticals
- training and education 281–282
- treatment (in cancer)  
brain tumors *see* brain tumors  
tumors  
breast cancer, response evaluation 144  
follow-up *see* follow-up  
GI tract tumors  
esophageal carcinoma, response evaluation 125, 126  
follow-up *see* follow-up  
GI tract tumors  
esophageal carcinoma, response evaluation 125, 126  
gastric carcinoma, decision making 126  
pancreatic cancer, decision making 129  
stromal tumors, response evaluation 132
- head and neck cancer, response evaluation 82–83
- lung cancer (non-small cell) individualized 111  
response evaluation 113
- lung cancer (small cell) 113
- lymphoma, response evaluation 179, 179–180, 182  
children 211
- melanoma 188  
response evaluation 192–193
- musculoskeletal tumors, response evaluation 205–206, 245  
children 217
- pediatric tumors 209
- pelvic tumors (females), response evaluation 146, 243
- prostatic carcinoma 171
- recurrence following *see* recurrence
- renal cell carcinoma, response evaluation 159
- response evaluation (in general) 240
- testicular tumors, response evaluation 164–165
- thyroid cancer, multimodal 88–93  
*see also specific tumor sites and modes of therapy*
- tumor(s)/neoplasms (incl. malignant tumors/cancer and oncology) 1, 61–246  
adrenal *see* adrenal tumors  
artifacts associated with  
benign tumors 48  
hypometabolic tumors 47–48
- brain *see* brain tumors  
FDG metabolism in 17
- gastrointestinal *see* gastrointestinal tract
- genitalia *see* genitalia
- head and neck *see* head and neck
- liver *see* liver
- lymphoid 177–187
- musculoskeletal *see* musculoskeletal system
- pancreatic 128–132
- pediatric *see* children
- prostatic *see* prostatic carcinoma
- radiopharmaceuticals used with 20, 21, 22
- respiratory tract (lower) *see* lung cancer; pleural mesothelioma
- secondary *see* metastases
- skin *see* melanoma
- testicular (germ cell) 162–167, 243
- thyroid 85–94, 242
- treatment *see* treatment
- unknown primary 81, 222–225, 246
- urinary tract 157–161, 243  
*see also specific types*
- tumor markers  
cervical cancer 148  
germ cell tumors (males) 162  
prostatic carcinoma 170, 172
- tunnel length 11
- U**
- ulcerative colitis 256, 257
- ultrasound  
breast cancer 141  
in follow-up 142  
cervical cancer 148  
ovarian cancer 146  
testicular cancer 163  
thyroid cancer 86–87  
postoperative staging 90  
for suspected recurrence 90, 93  
*see also* echocardiography
- undifferentiated tumors *see* entries under anaplastic
- unknown origin  
cancer of 81, 222–225, 246  
fever of 248–249, 259
- uptake (radiotracer) [<sup>18</sup>F]FDG *see* fluorodeoxyglucose  
quantification 35–36, 60  
skeletal 56–57  
time 34
- ureter, PET interpretation pitfalls 50, 55
- urinary tract  
cancer 157–161, 243  
PET interpretation pitfalls 55  
*see also specific regions/parts*
- uterus 145  
PET interpretation pitfalls 55
- V**
- vascular dementias 272
- vascular system  
graft infection 252  
inflammation (vasculitis) 254–256, 259  
pancreatic cancer involving 128
- Vater's ampulla, adenocarcinoma 130
- venous catheter 52
- volume acquisition 5, 289  
spiral CT 6
- W**
- water, <sup>15</sup>O- 23  
myocardial perfusion assessment 23, 263
- WHO *see* World Health Organization
- whole-body PET-CT with low-dose CT 30, 32
- Wilms' tumors 228, 229
- women *see* females
- World Health Organization classification  
brain tumors 61, 62–63  
lymphomas 178  
musculoskeletal tumors 194
- wound healing 48
- X**
- X-ray, personnel safety 13
- X-ray radiography  
bone tumors 195  
breast (mammography) 140–141  
chest (cervical cancer metastases) 148  
inflammatory bowel disease 257
- 5-hydroxytryptophan (5-HTP), medullary thyroid carcinoma 94